Regeneron Pharmaceuticals Inc. agreed to lower its U.S. drug prices as part of a deal with President Donald Trump, sending its shares up more than 2% on April 23.
"The White House will announce a drug pricing deal with Regeneron Pharmaceuticals on Thursday," a source familiar with the matter said, according to Reuters.
The agreement makes Regeneron the last of 17 large pharmaceutical companies to sign such a deal after receiving letters from the Trump administration in July. The company also committed to providing its new hearing-loss gene therapy for free to eligible U.S. patients after it receives regulatory approval.
This deal could set a precedent for other pharmaceutical companies, potentially leading to sector-wide pressure on drug pricing. For Regeneron, it may result in short-term revenue adjustments but could generate long-term goodwill and market share. The involvement of Trump could signal future healthcare policy directions, creating uncertainty for the industry.
This article is for informational purposes only and does not constitute investment advice.
